{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:36:33Z","timestamp":1787063793247,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder preservation therapy for muscle-invasive bladder cancer is reported to yield outcomes comparable to those of radical cystectomy, although it receives a relatively low recommendation grade in Japanese guidelines. This study aims to compare the outcomes of trimodal therapy versus radical cystectomy in the treatment of muscle-invasive bladder cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a single-center retrospective analysis that included patients treated with either trimodal therapy or radical cystectomy for muscle-invasive bladder cancer (cT2-4N0-2M0) at our institution between January 1998 and December 2022. Trimodal therapy is administered in cases where radical cystectomy is either unfeasible or declined by the patient, and both treatments are performed with the intent of curative outcomes. Propensity score matching was used to compare cancer-specific survival and overall survival rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 93 patients who underwent trimodal therapy and 84 who underwent radical cystectomy for muscle-invasive bladder cancer were analyzed. Using propensity score matching, 66 patients from each treatment group were selected for a comparative analysis of oncological outcomes. The 5-year distant metastasis-free, cancer-specific and overall survival rates were 64.3 and 51.8% (P\u00a0=\u00a00.096), 83.3 and 69.2% (P\u00a0=\u00a00.104) and 77.8 and 64.2% (P\u00a0=\u00a00.274) for trimodal therapy and radical cystectomy, respectively. Subgroup analyses revealed that trimodal therapy for primary tumors significantly improved cancer-specific survival rates compared with radical cystectomy. The two treatment types had similar adverse events related to hematologic toxicity during perioperative chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Trimodal therapy exhibited oncological outcomes comparable to those of radical cystectomy in the treatment of muscle-invasive bladder cancer, indicating that trimodal therapy provides favorable outcomes, particularly in cases of primary muscle-invasive bladder cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyae164","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T07:17:39Z","timestamp":1730791059000},"page":"290-296","source":"Crossref","is-referenced-by-count":4,"title":["Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-3156","authenticated-orcid":false,"given":"Keita","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakanori","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hitaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Hiroyoshi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Isoyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Yamaguchi University , Ube ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2025030608522359000_ref1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.eururo.2011.07.066","article-title":"External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder","volume":"61","author":"Nuhn","year":"2012","journal-title":"Eur Urol"},{"key":"2025030608522359000_ref2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/iju.14210","article-title":"Clinical practice guidelines for bladder cancer 2019 edition by the Japanese Urological Association: revision working position paper","volume":"27","author":"Matsumoto","year":"2020","journal-title":"Int J Urol"},{"key":"2025030608522359000_ref3","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.21037\/tau.2020.02.01","article-title":"Health-related quality of life after radical cystectomy","volume":"9","author":"Choi","year":"2020","journal-title":"Transl Androl Urol"},{"key":"2025030608522359000_ref4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2009.05.008","article-title":"Complications following radical cystectomy for bladder cancer in the elderly","volume":"56","author":"Froehner","year":"2009","journal-title":"Eur Urol"},{"key":"2025030608522359000_ref5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00345-009-0482-1","article-title":"Radical cystectomy in the elderly patient: a contemporary comparison of perioperative complications in a single institution series","volume":"28","author":"Tilki","year":"2010","journal-title":"World J Urol"},{"key":"2025030608522359000_ref6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.euf.2017.08.005","article-title":"Comparative perioperative outcomes in septuagenarians and octogenarians undergoing radical cystectomy for bladder cancer\u2014do outcomes differ?","volume":"4","author":"Haden","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2025030608522359000_ref7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"2025030608522359000_ref8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"2025030608522359000_ref9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"2025030608522359000_ref10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025030608522359000_ref11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bju.14736","article-title":"Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients","volume":"124","author":"Kijima","year":"2019","journal-title":"BJU Int"},{"key":"2025030608522359000_ref12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jjco\/hyac095","article-title":"The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study","volume":"52","author":"Kobayashi","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2025030608522359000_ref13","doi-asserted-by":"publisher","first-page":"1276746","DOI":"10.3389\/fsurg.2023.1276746","article-title":"Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis","volume":"10","author":"Al-Qudimat","year":"2023","journal-title":"Front Surg"},{"key":"2025030608522359000_ref14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12957-023-03161-z","article-title":"Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis","volume":"21","author":"Su","year":"2023","journal-title":"World J Surg Oncol"},{"key":"2025030608522359000_ref15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bju.16366","article-title":"Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies","volume":"134","author":"Ditonno","year":"2024","journal-title":"BJU Int"},{"key":"2025030608522359000_ref16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025030608522359000_ref17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/jnci\/djq121","article-title":"Use of radical cystectomy for patients with invasive bladder cancer","volume":"102","author":"Gore","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2025030608522359000_ref18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"2025030608522359000_ref19","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International Collaboration of Trialists","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025030608522359000_ref20","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025030608522359000_ref21","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3390\/cancers13102496","article-title":"Differential prognosis and response of DeNovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis","volume":"13","author":"Pones","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025030608522359000_ref22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","article-title":"Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study","volume":"39","author":"Grossmann","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"2025030608522359000_ref23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3892\/ijo_00000727","article-title":"Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation","volume":"37","author":"Azuma","year":"2010","journal-title":"Int J Oncol"},{"key":"2025030608522359000_ref24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint inhibitors in urothelial carcinoma-future directions and biomarker selection","volume":"84","author":"Meeks","year":"2023","journal-title":"Eur Urol"},{"key":"2025030608522359000_ref25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025030608522359000_ref26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1200\/JCO.2022.40.6_suppl.499","article-title":"Real-world study of chemotherapy plus immunotherapy versus chemotherapy alone as neoadjuvant treatment guided bladder-sparing therapy for localized muscle-invasive bladder cancer","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/3\/290\/60762449\/hyae164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/3\/290\/60762449\/hyae164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T03:52:30Z","timestamp":1741233150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/3\/290\/7905125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2025,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae164","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,20]]}}}